DataSheet_5_Associations of MDM2 rs2279744 and TP53 rs1042522 polymorphisms with cervical cancer risk: A meta-analysis and systematic review.docx

BackgroundAlthough the association between MDM2 rs2279744 and TP53 rs1042522 polymorphisms and cervical cancer has been reported, the results of its correlation were contradictory. Thus, we conducted a meta-analysis to precisely verify the relationships between MDM2 rs2279744 and TP53 rs1042522 polymorphisms and cervical cancer.MethodsWe thoroughly searched the PubMed, Web of Science, Embase, and Scopus databases for all potential articles from inception to June 2022 and used R Version 4.1.2 and STATA software 12.0 for the meta-analysis. The odds ratios (ORs), 95% confidence intervals (CIs) and 95% prediction intervals (PIs) were calculated to evaluate the associations. Subgroup analyses stratified by ethnicity, source of control, quality score and adjustment were further conducted to assess the relationship between MDM2 rs2279744 and TP53 rs1042522 polymorphisms and cervical cancer.ResultsA total of 30 case-control studies involving 5025 cases and 6680 controls were included. All the included studies were population-based or hospital-based studies. The overall analysis showed that MDM2 rs2279744 polymorphism was closely related to an increased risk of cervical cancer in the recessive model (GG vs GT + TT: OR = 1.602, 95% CI: 1.077-2.383, P = 0.020) and homozygote model (GG vs TT: OR = 1.469, 95% CI: 1.031-2.095, P = 0.033, 95% PI: 0.516-4.184). A significant correlation between TP53 rs1042522 polymorphism and cervical cancer was observed in two models (CC + CG vs GG: OR = 1.759, 95% CI: 1.192-2.596, P = 0.004, 95% PI: 0.474-6.533; GG vs CC: OR = 2.442, 95% CI: 1.433-4.162, P = 0.001, 95% PI: 0.456-13.071).ConclusionsThis meta-analysis revealed that MDM2 SNP309T>G and TP53 rs1042522 C>G polymorphisms were associated with the increased risk of cervical cancer.

尽管MDM2 rs2279744和TP53 rs1042522多态性与宫颈癌之间的关联已被报道，但其相关性研究结果存在矛盾。鉴于此，我们进行了一项荟萃分析，以精确验证MDM2 rs2279744和TP53 rs1042522多态性与宫颈癌之间的关联关系。方法：我们全面检索了PubMed、Web of Science、Embase和Scopus数据库中从起始至2022年6月期间的所有潜在文章，并使用R版本4.1.2和STATA软件12.0进行荟萃分析。通过计算比值比（ORs）、95%置信区间（CIs）和95%预测区间（PIs）来评估关联性。进一步按照种族、对照组来源、质量评分和调整进行亚组分析，以评估MDM2 rs2279744和TP53 rs1042522多态性与宫颈癌之间的关系。结果：共纳入30项病例对照研究，涉及5025例病例和6680名对照。总体分析显示，MDM2 rs2279744多态性与宫颈癌在隐性模型（GG vs GT + TT：OR = 1.602，95% CI：1.077-2.383，P = 0.020）和同质模型（GG vs TT：OR = 1.469，95% CI：1.031-2.095，P = 0.033，95% PI：0.516-4.184）中与宫颈癌发生风险增加密切相关。在两个模型中观察到TP53 rs1042522多态性与宫颈癌之间存在显著相关性（CC + CG vs GG：OR = 1.759，95% CI：1.192-2.596，P = 0.004，95% PI：0.474-6.533；GG vs CC：OR = 2.442，95% CI：1.433-4.162，P = 0.001，95% PI：0.456-13.071）。结论：本次荟萃分析揭示，MDM2单核苷酸多态性309T>G和TP53 rs1042522 C>G多态性与宫颈癌发生风险增加相关。